Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study.
Breast cancer
Microangiopathic haemolytic anaemia
Prognostic factors
Survival
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
19 01 2021
19 01 2021
Historique:
received:
24
08
2020
accepted:
01
01
2021
entrez:
20
1
2021
pubmed:
21
1
2021
medline:
7
1
2022
Statut:
epublish
Résumé
Cancer-related microangiopathic haemolytic anaemia (MAHA) is a rare but life-threatening paraneoplastic syndrome. Only single cases or small series have been reported to date. We set up a retrospective multicentre study focusing on breast cancer-related MAHA. Main inclusion criteria were known diagnosis of breast cancer, presence of schistocytes and either low haptoglobin or cytopenia and absence of any causes of MAHA other than breast cancer, including gemcitabine- or bevacizumab-based treatment. Patient characteristics, treatments and outcome were retrieved from digital medical records. Individual data from 54 patients with breast cancer-related MAHA were obtained from 7 centres. Twenty-three (44%) patients had a breast tumour with lobular features, and most primary tumours were low grade (grade I/II, N = 39, 75%). ER+/HER2-, HER2+ and triple-negative phenotypes accounted for N = 33 (69%), N = 7 (15%) and N = 8 (17%) cases, respectively. All patients had stage IV cancer at the time of MAHA diagnosis. Median overall survival (OS) was 28 days (range 0-1035; Q1:10, Q3:186). Independent prognostic factors for early death (≤ 28 days) were PS > 2 (OR = 7.0 [1.6; 31.8]), elevated bilirubin (OR = 6.9 [1.1; 42.6]), haemoglobin < 8.0 g/dL (OR = 3.7 [0.9; 16.7]) and prothrombin time < 50% (OR = 9.1 [1.2; 50.0]). A score to predict early death displayed a sensitivity of 86% (95% CI [0.67; 0.96]), a specificity of 73% (95% CI [0.52; 0.88]) and an area under the curve of 0.90 (95% CI [0.83; 0.97]). Breast cancer-related MAHA appears to be a new feature of invasive lobular breast carcinoma. Prognostic factors and scores may guide clinical decision-making in this serious but not always fatal condition.
Sections du résumé
BACKGROUND
Cancer-related microangiopathic haemolytic anaemia (MAHA) is a rare but life-threatening paraneoplastic syndrome. Only single cases or small series have been reported to date. We set up a retrospective multicentre study focusing on breast cancer-related MAHA.
METHODS
Main inclusion criteria were known diagnosis of breast cancer, presence of schistocytes and either low haptoglobin or cytopenia and absence of any causes of MAHA other than breast cancer, including gemcitabine- or bevacizumab-based treatment. Patient characteristics, treatments and outcome were retrieved from digital medical records.
RESULTS
Individual data from 54 patients with breast cancer-related MAHA were obtained from 7 centres. Twenty-three (44%) patients had a breast tumour with lobular features, and most primary tumours were low grade (grade I/II, N = 39, 75%). ER+/HER2-, HER2+ and triple-negative phenotypes accounted for N = 33 (69%), N = 7 (15%) and N = 8 (17%) cases, respectively. All patients had stage IV cancer at the time of MAHA diagnosis. Median overall survival (OS) was 28 days (range 0-1035; Q1:10, Q3:186). Independent prognostic factors for early death (≤ 28 days) were PS > 2 (OR = 7.0 [1.6; 31.8]), elevated bilirubin (OR = 6.9 [1.1; 42.6]), haemoglobin < 8.0 g/dL (OR = 3.7 [0.9; 16.7]) and prothrombin time < 50% (OR = 9.1 [1.2; 50.0]). A score to predict early death displayed a sensitivity of 86% (95% CI [0.67; 0.96]), a specificity of 73% (95% CI [0.52; 0.88]) and an area under the curve of 0.90 (95% CI [0.83; 0.97]).
CONCLUSIONS
Breast cancer-related MAHA appears to be a new feature of invasive lobular breast carcinoma. Prognostic factors and scores may guide clinical decision-making in this serious but not always fatal condition.
Identifiants
pubmed: 33468209
doi: 10.1186/s13058-021-01386-y
pii: 10.1186/s13058-021-01386-y
pmc: PMC7814553
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9Subventions
Organisme : Novartis
ID : N/A
Organisme : Institut Curie Siric 2
ID : INCa-DGOS-4654
Références
Crit Rev Oncol Hematol. 2014 Dec;92(3):235-57
pubmed: 25129506
Med Oncol. 2013 Mar;30(1):408
pubmed: 23322521
Medicine (Baltimore). 2012 Jul;91(4):195-205
pubmed: 22732949
South Med J. 1995 Jun;88(6):683-7
pubmed: 7777893
Breast Cancer. 1997 Mar 25;4(1):39-42
pubmed: 11091575
Mol Med. 2004 Jan-Jun;10(1-6):6-11
pubmed: 15502877
N Engl J Med. 2014 Aug 14;371(7):654-66
pubmed: 25119611
J Clin Invest. 2003 Sep;112(6):853-62
pubmed: 12975470
Ann Oncol. 2010 Nov;21(11):2183-2187
pubmed: 20430906
Eur J Haematol. 2010 Jul;85(1):43-50
pubmed: 20331741
Case Rep Oncol. 2014 Aug 27;7(2):605-10
pubmed: 25298767
Clin Cancer Res. 2009 Nov 15;15(22):6830-40
pubmed: 19861441
Medicine (Baltimore). 1977 Jan;56(1):1-37
pubmed: 834136
Cancer Res. 1999 May 1;59(9):2244-50
pubmed: 10232615
Ann Biol Clin (Paris). 2005 May-Jun;63(3):279-89
pubmed: 15951259
Br J Haematol. 1970 Feb;18(2):183-93
pubmed: 5439525
Br J Haematol. 2001 Apr;113(1):100-2
pubmed: 11328288
Oncologist. 2009 Aug;14(8):769-79
pubmed: 19684072
J Clin Oncol. 2008 May 20;26(15):2538-43
pubmed: 18487571
Br J Haematol. 1962 Oct;8:358-74
pubmed: 14014893
Oncologist. 2003;8(4):375-80
pubmed: 12897334
Am J Hematol. 2007 Apr;82(4):295-8
pubmed: 17034030
Ann Intern Med. 1973 Sep;79(3):368-75
pubmed: 4748253
Ann Oncol. 2008 Jun;19(6):1204-7
pubmed: 18407952
Am J Hematol. 1999 Aug;61(4):254-5
pubmed: 10440911
Br J Haematol. 2009 Apr;145(1):24-33
pubmed: 19222477
Am J Clin Oncol. 2000 Feb;23(1):74-7
pubmed: 10683084
Semin Oncol. 1990 Apr;17(2):172-86
pubmed: 2183359
J Thromb Haemost. 2015 Apr;13(4):671-5
pubmed: 25556711
Breast Care (Basel). 2011 Dec;6(6):441-445
pubmed: 22419897
Rev Med Interne. 2017 Nov;38(11):731-736
pubmed: 28890263
Medicine (Baltimore). 1979 Sep;58(5):377-84
pubmed: 481196
Ann Biol Clin (Paris). 2012 Oct 1;70(5):605-13
pubmed: 23047908
N Engl J Med. 2002 Aug 22;347(8):589-600
pubmed: 12192020
Fam Cancer. 2008;7(1):73-82
pubmed: 18046629
Med Klin (Munich). 2004 Mar 15;99(3):148-53
pubmed: 15024487
Springerplus. 2016 May 20;5(1):684
pubmed: 27350919
Br J Haematol. 2009 Aug;146(3):231
pubmed: 19183189
Oncologist. 2007 Jan;12(1):11-9
pubmed: 17227897
Eur J Cancer. 2018 Jun;96:17-24
pubmed: 29660596
Acta Haematol. 2003;109(3):150-2
pubmed: 12714826